VERESCA FOXC1 Phase III Triple Negative Breast Cancer Test Data Presented at ASCO 2024

Onconostic Technologies-3N Diagnostics Group (OT/3NDx), a leader in precision oncology diagnostics, today announced study results from the Phase III GEICAM/CIBOMA clinical trial involving patients diagnosed with triple-negative breast cancer (TNBC).